Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | LIPE | Q05469 | 4/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.32 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815314 | 0.88 | CACNA1B (0.36) | CCR2KCNH2LIPEMCHR1CACNA1B | |
| SCHEMBL14815225 | 0.86 | RBP4 (0.44) | CCR2KCNH2CACNA1B | |
| SCHEMBL14815371 | 0.86 | RBP4 (0.44) | CCR2KCNH2CACNA1B | |
| SCHEMBL14815444 | 0.84 | LIPE (0.42) | CCR2KCNH2LIPE | |
| SCHEMBL14815261 | 0.83 | LIPE (0.34) | CCR2KCNH2LIPEMCHR1 | |
| SCHEMBL14814741 | 0.83 | LIPE (0.39) | CCR2KCNH2LIPE | |
| SCHEMBL14814700 | 0.83 | KDM4E (0.44) | MCHR1PKM | |
| SCHEMBL14814839 | 0.83 | RET (0.33) | LIPEMAPK7 | |
| SCHEMBL14815265 | 0.83 | CCR2 (0.34) | CCR2KCNH2LIPE | |
| SCHEMBL14814823 | 0.82 | LIPE (0.34) | CCR2KCNH2LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | CCR2 2651/4885KCNH2 16/4885LIPE 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.